Responsiveness to interferon treatment of human melanoma cells correlates to immunophenotype

Melanoma Res. 1993 Feb;3(1):29-33. doi: 10.1097/00008390-199304000-00005.

Abstract

Clinical trials with interferon (INF) treatment in patients with advanced metastatic melanoma have met with limited success, suggesting that only a small subgroup of patients with melanoma is sensitive to INF therapy. For therapeutic strategies, it would be of great value to discriminate and define markers related to the anti-proliferative effects of INF. In the present study, we report on the in vitro growth inhibitory effects of INF in six human melanoma cell lines; this is associated with a modulation of cell surface markers. The responsiveness of human melanoma cell lines in vitro to INF-alpha shows a good correlation with a specific immunophenotype (TA99-/EGF-R+ or HLA-DR+). No marker correlated with sensitivity or resistance to INF-beta or INF-gamma. This is the first report identifying cell surface markers of human melanoma cells which might have a predictive value for the clinical response to INF-alpha.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Antigens, Neoplasm / analysis
  • Cell Division / drug effects
  • HLA-DR Antigens / analysis
  • Humans
  • Immunophenotyping
  • Interferon alpha-2
  • Interferon-alpha / pharmacology
  • Interferon-beta / pharmacology
  • Interferon-gamma / pharmacology
  • Interferons / pharmacology*
  • Melanoma / immunology*
  • Recombinant Proteins / pharmacology
  • Tumor Cells, Cultured

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • HLA-DR Antigens
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Interferon-beta
  • Interferon-gamma
  • Interferons